Evaluate Safety, Efficacy and Pharmacokinetics

• Status: Unknown status
• Trial end date: 2020-12-01
• Target enrollment: 0
• Participant gender: Female

Summary

The purpose of the study is to demonstrate equivalent pharmacokinetics (PK)

• Phase: Phase 1/Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Celltrion
• Treatments: Albumin-Bound Paclitaxel; Paclitaxel; Trastuzumab

Criteria

Inclusion Criteria:

• Are females

• Have a Her 2 over-expression

• Have ECOG 0 or 1

Exclusion Criteria:

• Current clinical or radiographic evidence CNS metastases

• Current Known infection

• Pregnant or nursing mother